Hormones
Hollis-Eden Pharmaceuticals Announces Reorganization
Published in Healthcare Mergers, Acquisitions and Ventures Week, May 19th, 2007
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced a restructuring designed to tightly focus the Company's future strategic direction on development of its proprietary class of adrenal steroid hormones in the therapeutic areas of metabolic disorders, autoimmune and other inflammatory conditions, and hormone sensitive cancers. Consistent with this focus, the Company's primary development efforts will be on clinical drug candidates HE3286 and HE3235, as well as follow-on compounds that may offer benefits in these therapeutic areas. With the Company's recent decision to discontinue investment in products for biodefense, Hollis-Eden is also reducing its headcount by 25% to effectively...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- AARP
AARP Launches Statewide Campaign for Health Care Reform - AARP Illinois
AARP Illinois Joins Governor in Fight for Health Care Reform - Abbott
Abbott Named Among the 'Top 10' on the Dave Thomas Foundation's '100 Best Adoption-Friendly Workplaces' List - Abbott
Abbott Reviews 2006 Accomplishments at Annual Shareholders' Meeting - Abiomed, Inc.
Abiomed, Inc. Announces Partial Exercise of Over-Allotment Option in Public Offering - Absorption Systems
New Publications on Brain Penetration - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
